Akums Strengthens PHN Treatment with Gabapentin ER Launch

Akums Drugs & Pharmaceuticals Ltd., India’s Largest Contract Development and Manufacturing Organization (CDMO), has announced the rollout of its Gabapentin Extended-Release formulation for the management of Postherpetic Neuralgia treatment. PHN is a condition associated with neuropathic pain after shingles, affecting nearly 10–20 percent of patients and becoming more debilitating with age. Symptoms such as burning sensations, shooting pain and allodynia significantly impact daily functioning and quality of life.

Gabapentin is widely prescribed for chronic neuropathic pain management, but conventional versions often require multiple doses per day and show inconsistent absorption. Akum’s new formulation integrates RetenEx Technology drug delivery, enabling gradual and sustained release of the drug along the gastrointestinal tract. This supports improved absorption, reduced peak-related side effects and once-daily pain medication, particularly beneficial for elderly patients.

Also Read: India's Rare Disease Shift Driven by PRIP and PLI Policies

Designed as a sustained-release pain therapy, Akums’ Gabapentin ER 300 mg and 600 mg tablets are DCGI approved Gabapentin ER options aimed at improving long-term adherence without compromising safety or efficacy. The formulation helps maintain stable plasma drug levels, reducing fluctuations that often trigger breakthrough pain.

“In chronic pain conditions like PHN, small gains in convenience can significantly improve quality of life. This enhanced Gabapentin ER supports stable pain control and better adherence, especially in elderly patient pain care,” said Sandeep Jain, Managing Director and Founder, Akums Drugs & Pharmaceuticals Ltd.

Clinical evidence, including studies published on PubMed, indicates that extended-release gabapentin is well tolerated and shows positive outcomes in long-term PHN management. With this launch, Akums continues to strengthen its portfolio of advanced drug delivery technologies, reinforcing its commitment to improving access to effective pain management therapies across India.